OKUR · OnKure Therapeutics, Inc.
$3.93
-0.15 (-3.68%)
At close · Aug 20
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Market Cap
$165.22M
Shares
40.50M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.93
Open$4.04
Day$3.78–4.04
52W close$2.32–5.27
Avg vol 30d129K
Short int1.2M · 2.9% float · 10.6d
Short vol48%
Last earningsAug 12, 2025
DataOct 2024–Aug 2026
Filing10-Q · Aug 4
Raw chart and full-history price indicators begin at the captured split on Oct 7, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
−7%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
55%
mid-range
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+45%
trailing
YTD return
+36%
this year
Relative strength
+34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+47% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$1.7K over 90 days · 100% sells
Short interest
Rising
2.93% of float · ▲ +0.5% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
75 holders — near 2-yr high, broad support
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
+71%
Y/Y
Free cash flow
$-51.9M
Balance sheet
$59.1M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
−7%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
55%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+47% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$1.7K over 90 days · 100% sells
Short interest
Rising
2.93% of float · ▲ +0.5% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
75 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $4 · 55%
Range high $5
vs 200-day avg +8%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients dosed across both Parts A and B of PIKture-01 | 71 | as of the date of the release | — |
| Patients dosed in fulvestrant combination arm (Part B) | 33 | as of the date of the release | — |
| Patients dosed in monotherapy arm (Part A) | 38 | as of the date of the release | — |
| Patients dosed in Part E (OKI-219 + fulvestrant + ribociclib triplet) | 17 | as of the date of the release | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OKUR
this stock
OnKure Therapeutics, Inc.
|
$165.22M | +35.5% | — | — | 2.9% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Oct 7, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OKUR | +0.8% | -6.9% | +45.0% | +2.9% | +35.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.7% | -10.2% | +33.9% | +0.8% | +23.7% |
Key facts
CIK
1637715
CUSIP
68277Q105
13F (30d)
76 filings
74 filers
Visit website
Investor relations